After giving up on its migraine drug MT 100 last week, Pozen Inc. has submitted a new drug application for another therapy targeting the same condition - Trexima, which is a pill that combines sumatriptan succinate and one of MT 100's ingredients, naproxen sodium. (BioWorld Today) Read More
